Literature DB >> 19164509

Suppressive effect of orthovanadate on hepatic stellate cell activation and liver fibrosis in rats.

Yuji Nishikawa1, Naoto Ohi, Akiko Yagisawa, Yuko Doi, Yohei Yamamoto, Masayuki Yoshida, Takuo Tokairin, Toshiaki Yoshioka, Yasufumi Omori, Katsuhiko Enomoto.   

Abstract

Orthovanadate (OV), an inhibitor of protein tyrosine phosphatases, affects various biological processes in a cell-type-specific manner. In this study, we investigated the effect of OV on hepatic stellate cells (HSCs). When primary rat HSCs were cultured in the presence of 10% serum, they spontaneously lost characteristic stellate morphology, proliferated, and were transformed into an activated state with the formation of abundant stress fibers and increased expression of both alpha-smooth muscle actin and collagen type I mRNA. OV treatment inhibited proliferation and activation of HSCs and partially reversed the phenotype of activated HSCs. Among the signaling molecules investigated, phosphorylation of the Src protein at tyrosine 416 was the most striking in OV-treated HSCs. Treatment of cells with Src family inhibitors partially abrogated the effects of OV. Furthermore, transfection of v-Src into activated HSCs induced a stellate morphology similar to that in the quiescent state. We then examined whether OV could effectively suppress HSC activation in vivo after liver injury induced by either carbon tetrachloride or dimethylnitrosamine. OV significantly reduced the appearance of alpha-smooth muscle actin-positive cells and decreased collagen deposition, concomitant with an improvement in liver function. Our study showed for the first time that OV was able to suppress the activation of HSCs, possibly through the modulation of Src activity, and attenuated fibrosis after chronic liver injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164509      PMCID: PMC2665748          DOI: 10.2353/ajpath.2009.080261

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth.

Authors:  H Iwamoto; M Nakamuta; S Tada; R Sugimoto; M Enjoji; H Nawata
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

2.  Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism.

Authors:  W T Arthur; L A Petch; K Burridge
Journal:  Curr Biol       Date:  2000-06-15       Impact factor: 10.834

3.  A src family tyrosine kinase inhibits neurotransmitter release from neuronal cells.

Authors:  H Ohnishi; S Yamamori; K Ono; K Aoyagi; S Kondo; M Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

4.  Thy-1 is an in vivo and in vitro marker of liver myofibroblasts.

Authors:  Jozsef Dudas; Tümen Mansuroglu; Danko Batusic; Bernhard Saile; Giuliano Ramadori
Journal:  Cell Tissue Res       Date:  2007-06-19       Impact factor: 5.249

5.  Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. Significance of protein tyrosine phosphatase inhibition.

Authors:  Y Nishikawa; Z Wang; J Kerns; C S Wilcox; B I Carr
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

6.  Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway.

Authors:  Dominique Brandt; Mario Gimona; Meike Hillmann; Hermann Haller; Harald Mischak
Journal:  J Biol Chem       Date:  2002-03-29       Impact factor: 5.157

7.  Peroxisome proliferator-activated receptors and hepatic stellate cell activation.

Authors:  T Miyahara; L Schrum; R Rippe; S Xiong; H F Yee; K Motomura; F A Anania; T M Willson; H Tsukamoto
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

8.  Systemic vanadate ingestion modulates rat tendon repair.

Authors:  Kurtis E Moyer; Amer A Saba; Randy M Hauck; H Paul Ehrlich
Journal:  Exp Mol Pathol       Date:  2003-08       Impact factor: 3.362

9.  Therapeutic significance of Y-27632, a Rho-kinase inhibitor, on the established liver fibrosis.

Authors:  Toru Murata; Shigeki Arii; Akira Mori; Masayuki Imamura
Journal:  J Surg Res       Date:  2003-09       Impact factor: 2.192

10.  Cell adhesion regulates platelet-derived growth factor-induced MAP kinase and PI-3 kinase activation in stellate cells.

Authors:  Vinicio Carloni; Raffaella M S Defranco; Alessandra Caligiuri; Alessandra Gentilini; Silvia Cappadona Sciammetta; Elisabetta Baldi; Benedetta Lottini; Paolo Gentilini; Massimo Pinzani
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  5 in total

1.  Functional impact of PTP1B-mediated Src regulation on oxidative phosphorylation in rat brain mitochondria.

Authors:  Etienne Hébert Chatelain; Jean-William Dupuy; Thierry Letellier; Jeanne Dachary-Prigent
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

2.  MR Imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrin-targeted ultrasmall superparamagnetic iron oxide.

Authors:  Qing-Bing Wang; Yu Han; Ting-Ting Jiang; Wei-Min Chai; Ke-Min Chen; Bing-Ya Liu; Li-Fu Wang; Chunfu Zhang; Deng-Bin Wang
Journal:  Eur Radiol       Date:  2010-10-25       Impact factor: 5.315

3.  Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis.

Authors:  Gibran Ali; Sadia Mohsin; Mohsin Khan; Ghazanfar Ali Nasir; Sulaiman Shams; Shaheen N Khan; Sheikh Riazuddin
Journal:  J Transl Med       Date:  2012-04-25       Impact factor: 5.531

4.  High-frequency ultrasound imaging to evaluate liver fibrosis progression in rats and yi guan jian herbal therapeutic effects.

Authors:  Wei Chen; Jiun-Yu Chen; Yu-Tang Tung; Hsiao-Ling Chen; Chia-Wen Kuo; Chia-Hui Chuang; Kowit-Yu Chong; Frank Chiahung Mao; Chuan-Mu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-23       Impact factor: 2.629

5.  c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer.

Authors:  Caroline A Hunter; Hasan Koc; Emine C Koc
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.